RSV – Talk Bio

Sanofi Tightens Grip on RSV with $1.15B Upfront Acquisition of Vicebio, Diversifying Beyond mRNA Vaccines

4 days ago talkbio0Tagged Acquisition, Homo sapiens, Metapneumovirus, Molecular Clamp Technology, non-mRNA vaccine, Respiratory syncytial virus, respiratory vaccines, RSV, sanofi, vaccine pipeline, Vaccines, Combined, Vicebio

Sanofi; Vicebio; acquisition; RSV; human metapneumovirus; combination vaccine; Molecular Clamp technology; non-mRNA vaccine; vaccine pipeline; respiratory vaccines

ACIP Backs Merck’s Enflonsia for RSV Prevention in Infants

4 weeks ago talkbio0Tagged ACIP, Children Program, Enflonsia, Immunization, Infant, Merck, Monoclonal Antibodies, Respiratory syncytial virus, RSV, Vaccines

ACIP; Merck; Enflonsia; RSV; monoclonal antibody; infants; immunization; Vaccines for Children Program

Pfizer Terminates Development of Oral RSV Medication Sisunatovir Due to Ongoing Challenges

10 months ago talkbio0Tagged Acquisition (action), Clinical Development, Pfizer, Respiratory syncytial virus, ReViral, RSV, sisunatovir, Termination - Inactive Reason Code

Pfizer, ReViral, RSV, Sisunatovir, Acquisition, Clinical Development, Termination